Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Rating of "Buy" from Analysts

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have been assigned an average recommendation of "Buy" from the nine research firms that are covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $25.67.

Several equities analysts recently commented on the stock. Mizuho decreased their price target on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a research note on Friday, May 16th. Royal Bank Of Canada assumed coverage on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, June 17th. They issued an "outperform" rating and a $28.00 price target on the stock. Chardan Capital reduced their price objective on shares of Eyepoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. Finally, HC Wainwright reiterated a "buy" rating and set a $22.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Thursday, May 29th.

Eyepoint Pharmaceuticals Stock Performance

Shares of EYPT stock traded up $1.01 on Friday, hitting $10.96. The company's stock had a trading volume of 1,395,822 shares, compared to its average volume of 822,410. The stock's 50 day moving average is $7.87 and its 200-day moving average is $7.09. Eyepoint Pharmaceuticals has a fifty-two week low of $3.91 and a fifty-two week high of $13.99. The company has a market capitalization of $754.16 million, a PE ratio of -4.55 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) EPS for the quarter, meeting the consensus estimate of ($0.65). Eyepoint Pharmaceuticals had a negative net margin of 261.91% and a negative return on equity of 54.27%. The business had revenue of $24.50 million for the quarter, compared to the consensus estimate of $8.84 million. On average, research analysts forecast that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Summit Investment Advisors Inc. lifted its holdings in shares of Eyepoint Pharmaceuticals by 39.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock worth $51,000 after acquiring an additional 1,940 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Eyepoint Pharmaceuticals in the fourth quarter worth about $59,000. Virtus ETF Advisers LLC bought a new position in shares of Eyepoint Pharmaceuticals in the fourth quarter worth about $67,000. AlphaQuest LLC lifted its holdings in shares of Eyepoint Pharmaceuticals by 13,246.6% in the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company's stock worth $73,000 after acquiring an additional 9,670 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Eyepoint Pharmaceuticals in the 4th quarter valued at approximately $76,000. Institutional investors own 99.41% of the company's stock.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.